Development
Tarsus Pharmaceuticals, Inc.
TARS
$41.15
-$0.76-1.81%
NASDAQ
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 598.88% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 598.88% | -- | |||
| Cost of Revenue | 16.34% | -0.51% | |||
| Gross Profit | 86.38% | 15.42% | |||
| SG&A Expenses | 41.82% | 49.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 34.39% | 30.42% | |||
| Operating Income | -8.59% | -24.72% | |||
| Income Before Tax | -7.03% | -24.58% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -7.03% | -24.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.03% | -24.58% | |||
| EBIT | -8.59% | -24.72% | |||
| EBITDA | -8.39% | -24.67% | |||
| EPS Basic | -2.60% | -9.10% | |||
| Normalized Basic EPS | 3.07% | -8.57% | |||
| EPS Diluted | -2.60% | -9.10% | |||
| Normalized Diluted EPS | 3.07% | -8.57% | |||
| Average Basic Shares Outstanding | 4.32% | 14.20% | |||
| Average Diluted Shares Outstanding | 4.32% | 14.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||